Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | 2C18H21NO3.H2O.2H3O4P |
| Molecular Weight | 812.7341 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 10 / 10 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.OP(O)(O)=O.OP(O)(O)=O.[H][C@@]12OC3=C4C(C[C@H]5N(C)CC[C@@]14[C@@]5([H])C=C[C@@H]2O)=CC=C3OC.[H][C@@]67OC8=C9C(C[C@H]%10N(C)CC[C@@]69[C@@]%10([H])C=C[C@@H]7O)=CC=C8OC
InChI
InChIKey=DKSZLDSPXIWGFO-BLOJGBSASA-N
InChI=1S/2C18H21NO3.2H3O4P.H2O/c2*1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19;2*1-5(2,3)4;/h2*3-6,11-13,17,20H,7-9H2,1-2H3;2*(H3,1,2,3,4);1H2/t2*11-,12+,13-,17-,18-;;;/m00.../s1
| Molecular Formula | H2O |
| Molecular Weight | 18.0153 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | H3O4P |
| Molecular Weight | 97.9952 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C18H21NO3 |
| Molecular Weight | 299.3642 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Codeine is an opiate used to manage mild to moderate pain severe enough to require an opioid. Codeine is a selective agonist for the mu opioid receptor and has an affinity to delta and kappa-opioid receptors. In some countries, this drug is regulated under various narcotic control laws, because its chronic use can cause physical dependence. In others, it is available without a medical prescription in combination with paracetamol.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL233 |
6.1 µM [EC50] | ||
Target ID: P41145 Gene ID: 4986.0 Gene Symbol: OPRK1 Target Organism: Homo sapiens (Human) |
|||
Target ID: P41143 Gene ID: 4985.0 Gene Symbol: OPRD1 Target Organism: Homo sapiens (Human) |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | CAPITAL AND CODEINE Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Analgesic abuse, ureteric obstruction, and retroperitoneal fibrosis. | 1975 Apr 12 |
|
| Dystonia as acute adverse reaction to cough suppressant in a 3-year-old girl. | 2001 |
|
| [Guillain-Barre syndrome as a result of poisoning with a mixture of "kompot"(Polish heroin) and drugs]. | 2001 |
|
| Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis. | 2001 |
|
| Saliva testing after single and chronic administration of dihydrocodeine. | 2001 |
|
| The use of compound 48/80 and codeine phosphate as positive controls for intradermal skin testing in dogs. | 2001 Apr |
|
| Chromatographic analysis of phenethylamine-antihistamine combinations using C8, C18 or cyano columns and micellar sodium dodecyl sulfate-pentanol mixtures. | 2001 Apr |
|
| The diagnosis and treatment of cough. | 2001 Apr 5 |
|
| Simultaneous determination of codeine and ethyl morphine HCL in tablet formulations using LC. | 2001 Aug |
|
| Prescribing limitations. | 2001 Aug 11 |
|
| Precipitated withdrawal following codeine administration is dependent on CYP genotype. | 2001 Aug 17 |
|
| Inhibition by glucocorticoids of the mast cell-dependent weal and flare response in human skin in vivo. | 2001 Jan |
|
| Using evidence from different sources: an example using paracetamol 1000 mg plus codeine 60 mg. | 2001 Jan 10 |
|
| Opiate-sensitivity: clinical characteristics and the role of skin prick testing. | 2001 Jul |
|
| Contribution of dihydrocodeine and dihydromorphine to analgesia following dihydrocodeine administration in man: a PK-PD modelling analysis. | 2001 Jul |
|
| Head-column field-amplified sample stacking in presence of siphoning. Application to capillary electrophoresis-electrospray ionization mass spectrometry of opioids in urine. | 2001 Jul 27 |
|
| Use of beta-cyclodextrin in the capillary zone electrophoretic separation of the components of clandestine heroin preparations. | 2001 Jul 27 |
|
| Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. | 2001 Jul 7 |
|
| Successful withdrawal from analgesic abuse in a group of youngsters with chronic daily headache. | 2001 Jun |
|
| Codeine phosphate in paediatric medicine. | 2001 Mar |
|
| Myocardial Infarction associated with methadone and/or dihydrocodeine. | 2001 Mar |
|
| GC-MS determination of heroin metabolites in meconium: evaluation of four solid-phase extraction cartridges. | 2001 Mar |
|
| Treatment of severe pain from osteoarthritis with slow-release tramadol or dihydrocodeine in combination with NSAID's: a randomised study comparing analgesia, antinociception and gastrointestinal effects. | 2001 Mar |
|
| The analgesic effect of codeine as compared to imipramine in different human experimental pain models. | 2001 May |
|
| From codeine to transdermal fentanyl for cancer pain control: a safety and efficacy clinical trial. | 2001 May-Jun |
|
| Application of liquid chromatography to the simultaneous determination of acetylsalicylic acid, caffeine, codeine, paracetamol, pyridoxine, and thiamine in pharmaceutical preparations. | 2001 May-Jun |
|
| The role of adrenal corticosteroids in induction of micronuclei by morphine. | 2001 Nov 15 |
|
| Novel dynamic polymer coating for capillary electrophoresis in nonaqueous methanolic background electrolytes. | 2001 Oct |
|
| Analysis of morphine and codeine in samples adulterated with Stealth. | 2001 Oct |
|
| Ropivacaine with or without clonidine improves pediatric tonsillectomy pain. | 2001 Oct |
|
| Drug contamination of US paper currency. | 2001 Oct 1 |
|
| Community pharmacists' experience of over-the-counter medicine misuse in Scotland. | 2001 Sep |
|
| Cetirizine inhibits skin reactions but not mediator release in immediate and developing late-phase allergic cutaneous reactions. A double-blind, placebo-controlled study. | 2001 Sep |
|
| Concentration ratios of codeine-to-morphine in plasma after a single oral dose (100 mg) of codeine phosphate. | 2001 Sep |
|
| Pain control in medical abortion. | 2001 Sep |
|
| Engineering novel biocatalytic routes for production of semisynthetic opiate drugs. | 2001 Sep |
|
| Can standard open pediatric urological procedures be performed on an outpatient basis? | 2001 Sep |
|
| Experience with urine drug testing by the Correctional Service of Canada. | 2001 Sep 15 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:09:33 GMT 2023
by
admin
on
Fri Dec 15 15:09:33 GMT 2023
|
| Record UNII |
GSL05Y1MN6
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
CFR |
21 CFR 1308.15
Created by
admin on Fri Dec 15 15:09:33 GMT 2023 , Edited by admin on Fri Dec 15 15:09:33 GMT 2023
|
||
|
CFR |
21 CFR 290.2
Created by
admin on Fri Dec 15 15:09:33 GMT 2023 , Edited by admin on Fri Dec 15 15:09:33 GMT 2023
|
||
|
NCI_THESAURUS |
C1657
Created by
admin on Fri Dec 15 15:09:33 GMT 2023 , Edited by admin on Fri Dec 15 15:09:33 GMT 2023
|
||
|
DEA NO. |
9050
Created by
admin on Fri Dec 15 15:09:33 GMT 2023 , Edited by admin on Fri Dec 15 15:09:33 GMT 2023
|
||
|
CFR |
21 CFR 341.14
Created by
admin on Fri Dec 15 15:09:33 GMT 2023 , Edited by admin on Fri Dec 15 15:09:33 GMT 2023
|
||
|
CFR |
21 CFR 341.74
Created by
admin on Fri Dec 15 15:09:33 GMT 2023 , Edited by admin on Fri Dec 15 15:09:33 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB29134
Created by
admin on Fri Dec 15 15:09:33 GMT 2023 , Edited by admin on Fri Dec 15 15:09:33 GMT 2023
|
PRIMARY | |||
|
DTXSID20904612
Created by
admin on Fri Dec 15 15:09:33 GMT 2023 , Edited by admin on Fri Dec 15 15:09:33 GMT 2023
|
PRIMARY | |||
|
DBSALT000030
Created by
admin on Fri Dec 15 15:09:33 GMT 2023 , Edited by admin on Fri Dec 15 15:09:33 GMT 2023
|
PRIMARY | |||
|
100000090188
Created by
admin on Fri Dec 15 15:09:33 GMT 2023 , Edited by admin on Fri Dec 15 15:09:33 GMT 2023
|
PRIMARY | |||
|
6321303
Created by
admin on Fri Dec 15 15:09:33 GMT 2023 , Edited by admin on Fri Dec 15 15:09:33 GMT 2023
|
PRIMARY | |||
|
C74548
Created by
admin on Fri Dec 15 15:09:33 GMT 2023 , Edited by admin on Fri Dec 15 15:09:33 GMT 2023
|
PRIMARY | |||
|
1144000
Created by
admin on Fri Dec 15 15:09:33 GMT 2023 , Edited by admin on Fri Dec 15 15:09:33 GMT 2023
|
PRIMARY | |||
|
41444-62-6
Created by
admin on Fri Dec 15 15:09:33 GMT 2023 , Edited by admin on Fri Dec 15 15:09:33 GMT 2023
|
PRIMARY | |||
|
CHEMBL485
Created by
admin on Fri Dec 15 15:09:33 GMT 2023 , Edited by admin on Fri Dec 15 15:09:33 GMT 2023
|
PRIMARY | |||
|
2672
Created by
admin on Fri Dec 15 15:09:33 GMT 2023 , Edited by admin on Fri Dec 15 15:09:33 GMT 2023
|
PRIMARY | RxNorm | ||
|
CODEINE PHOSPHATE
Created by
admin on Fri Dec 15 15:09:33 GMT 2023 , Edited by admin on Fri Dec 15 15:09:33 GMT 2023
|
PRIMARY | Description: Small, colourless crystals or a white, crystalline powder; odourless.Solubility: Soluble in 4 parts of water; slightly soluble in ethanol (~750 g/l) TS; practically insoluble in ether R.Category: Antitussive; analgesic.Storage: Codeine phosphate should be kept in a tightly closed container, protected from light.Labelling: The designation on the container should state if the Codeine phosphate is the hemihydrate or the sesquihydrate.Additional information. Codeine phosphate effloresces in dry air. | ||
|
GSL05Y1MN6
Created by
admin on Fri Dec 15 15:09:33 GMT 2023 , Edited by admin on Fri Dec 15 15:09:33 GMT 2023
|
PRIMARY | |||
|
GSL05Y1MN6
Created by
admin on Fri Dec 15 15:09:33 GMT 2023 , Edited by admin on Fri Dec 15 15:09:33 GMT 2023
|
PRIMARY | |||
|
SUB13428MIG
Created by
admin on Fri Dec 15 15:09:33 GMT 2023 , Edited by admin on Fri Dec 15 15:09:33 GMT 2023
|
PRIMARY | |||
|
SUB13427MIG
Created by
admin on Fri Dec 15 15:09:33 GMT 2023 , Edited by admin on Fri Dec 15 15:09:33 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
ANHYDROUS->SOLVATE | |||
|
SOLVATE->ANHYDROUS |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |